Reverse Split Ratio
|
| |
Approximate Number of New Shares
Following the Reverse Split |
| |||
1-for-15
|
| | | | 13,117,546 | | |
1-for-20
|
| | | | 9,838,159 | | |
1-for-25
|
| | | | 7,870,528 | | |
1-for-30
|
| | | | 6,558,773 | | |
Reverse Split Ratio
|
| |
Approximate Number of Underlying Shares
Following the Reverse Split |
| |||
1-for-15
|
| | | | 7,121,970 | | |
1-for-20
|
| | | | 5,341,477 | | |
1-for-25
|
| | | | 4,273,182 | | |
1-for-30
|
| | | | 3,560,985 | | |
Name and Address of Beneficial Owner(1)
|
| |
Shares Beneficially
Owned(2) |
| |
Percent of Shares
Beneficially Owned |
| ||||||
Joseph A. Akers(3)
|
| | | | 74,974 | | | | | | *% | | |
Sunil Bhonsle(4)
|
| | | | 309,155 | | | | | | * | | |
Kate Devarney, Ph.D.(5)
|
| | | | 55,876 | | | | | | * | | |
M. David MacFarlane, Ph.D.(6)
|
| | | | 39,327 | | | | | | * | | |
James R. McNab, Jr.(7)
|
| | | | 89,475 | | | | | | * | | |
Marc Rubin, M.D.(8)
|
| | | | 329,250 | | | | | | * | | |
Scott A. Smith(9)
|
| | | | 2,501 | | | | | | * | | |
All executive officers and directors as a group (7) persons
|
| | | | 900,558 | | | | | | *% | | |
☐ FOR
|
☐ AGAINST
|
☐ ABSTAIN |
| | | | Titan Pharmaceuticals, Inc. | | |||
| | | | By: | | |
/s/ Kate Devarney, Ph.D.
Kate Devarney, PhD., President and Chief Operating Officer
|
|